Concord Drugs share news and announcements
BSE: 538965Pharmaceuticals & BiotechnologySmall Cap
Last close ₹68.06down ₹0.94 (1.36%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹69.00.
52-week range of traded prices to 23 Oct 2026
₹61.00Low, 23 Oct 2025₹92.52High, 13 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90 Cr3,001st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 43.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 5.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 7.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.28
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,703
Concord Drugs share news and announcements
433 announcements, routine notices left out, newest first. Page 2 of 9.
Jul 2025
3 Jul · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
3 Jul · Board meeting
2 Jul · Legal
2 Jul · Legal
Exchange has sought clarification from Concord Drugs Ltd on July 2, 2025, with reference to Movement in Price The reply is awaited.
Jun 2025
30 Jun · Board meeting
Meeting on 3 Jul 2025: increase in authorised capital and preferential issue of shares27 Jun · Board meeting
19 Jun · Board meeting
Meeting on 27 Jun 2025: preferential issue of shares
May 2025
16 May · Board meeting
Meeting on 23 May 2025: audited results
Mar 2025
17 Mar · Board meeting
13 Mar · Board meeting
Meeting on 17 Mar 2025: increase in authorised capital and preferential issue of shares4 Mar · Board meeting
Meeting on 13 Mar 2025: increase in authorised capital and preferential issue of shares
Jan 2025
11 Jan · Results
7 Jan · Board meeting
Meeting on 11 Jan 2025: quarterly results
Nov 2024
6 Nov · Board meeting
Meeting on 13 Nov 2024: quarterly results
Oct 2024
Sep 2024
30 Sep · Board meeting
12 Sep · Results
6 Sep · Board meeting
2 Sep · Board meeting
Meeting on 6 Sep 2024: increase in authorised capital and preferential issue of shares
Aug 2024
9 Aug · Board meeting
5 Aug · Board meeting
Meeting on 9 Aug 2024: quarterly results
May 2024
30 May · Board meeting
15 May · Board meeting
Meeting on 30 May 2024: audited results
Apr 2024
30 Apr · Compliance Under Regulation 40(9) Of SEBI (LODR)
30 Apr · For Year Ended 31.03.2024